JOP20210161A1 - Substituted oxopyridine derivatives - Google Patents

Substituted oxopyridine derivatives

Info

Publication number
JOP20210161A1
JOP20210161A1 JOP/2021/0161A JOP20210161A JOP20210161A1 JO P20210161 A1 JOP20210161 A1 JO P20210161A1 JO P20210161 A JOP20210161 A JO P20210161A JO P20210161 A1 JOP20210161 A1 JO P20210161A1
Authority
JO
Jordan
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
thrombotic
Prior art date
Application number
JOP/2021/0161A
Other languages
Arabic (ar)
Inventor
Neubauer Thomas
Stampfuss Jan
Lang Dieter
Tersteegen Adrian
Hillisch Alexander
Ellerbrock Pascal
Zou Zengqiang
Essig Sebastian
Heitmeier Stefan
R?HRIG Susanne
Anlauf Sonja
Meng Xianghai
Meier Katharina
Matthias Gericke Kersten
SCH?FER Martina
Wang Hongping
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of JOP20210161A1 publication Critical patent/JOP20210161A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
JOP/2021/0161A 2018-12-21 2019-12-18 Substituted oxopyridine derivatives JOP20210161A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
JOP20210161A1 true JOP20210161A1 (en) 2023-01-30

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0161A JOP20210161A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Country Status (22)

Country Link
EP (1) EP3898633A1 (en)
JP (1) JP2022514303A (en)
KR (1) KR20210106504A (en)
CN (1) CN113474348A (en)
AR (1) AR117435A1 (en)
AU (1) AU2019407909B2 (en)
BR (1) BR112021009435A2 (en)
CA (1) CA3124220A1 (en)
CL (1) CL2021001613A1 (en)
CO (1) CO2021007908A2 (en)
CR (1) CR20210342A (en)
DO (1) DOP2021000128A (en)
EA (1) EA202191764A1 (en)
EC (1) ECSP21043895A (en)
IL (1) IL283990A (en)
JO (1) JOP20210161A1 (en)
MA (1) MA54521A (en)
MX (1) MX2021007508A (en)
PE (1) PE20211790A1 (en)
SG (1) SG11202104384PA (en)
TW (1) TW202039510A (en)
WO (1) WO2020127504A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3765452T3 (en) * 2018-03-15 2022-08-01 Bayer Aktiengesellschaft Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
CN114105881B (en) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 Platelet aggregation inhibitor, and preparation method and application thereof
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
WO2022189278A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
KR20230155505A (en) 2021-03-09 2023-11-10 바이엘 악티엔게젤샤프트 (4S)-24-Chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32H-6-aza-3(4,1 )-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 crystalline form of dibenzenaheptaphane-74-carboxamide
CN114560754A (en) * 2022-02-25 2022-05-31 滁州学院 Preparation method of alkyl alcohol
CN116874469B (en) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 Oxo-pyridine compound, intermediate, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (en) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituted indazoles
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (en) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
WO2015011087A1 (en) 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
EP3063150B1 (en) 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2712886T3 (en) 2014-09-24 2019-05-16 Bayer Pharma AG Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa
ES2716417T3 (en) 2014-09-24 2019-06-12 Bayer Pharma AG Derivatives of oxopyridine substituted with anti-inflammatory and antithrombotic action
US10167280B2 (en) 2014-09-24 2019-01-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2722423T3 (en) * 2014-09-24 2019-08-12 Bayer Pharma AG Substituted oxopyridine derivatives
ES2694189T3 (en) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197873B1 (en) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016146606A1 (en) 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
EP3344618A1 (en) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
CR20210342A (en) 2021-08-09
AU2019407909B2 (en) 2023-05-25
CO2021007908A2 (en) 2021-07-19
IL283990A (en) 2021-07-29
MX2021007508A (en) 2021-08-05
MA54521A (en) 2022-03-30
CL2021001613A1 (en) 2021-12-03
SG11202104384PA (en) 2021-05-28
CA3124220A1 (en) 2020-06-25
AR117435A1 (en) 2021-08-04
EP3898633A1 (en) 2021-10-27
DOP2021000128A (en) 2021-09-30
CN113474348A (en) 2021-10-01
JP2022514303A (en) 2022-02-10
AU2019407909A1 (en) 2021-05-27
BR112021009435A2 (en) 2021-08-17
TW202039510A (en) 2020-11-01
WO2020127504A1 (en) 2020-06-25
EA202191764A1 (en) 2021-10-22
ECSP21043895A (en) 2021-07-30
KR20210106504A (en) 2021-08-30
PE20211790A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
CR20210342A (en) Substituted oxopyridine derivatives
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12020551973A1 (en) Substituted dihydropyrazolo pyrazine carboxamide derivatives
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
WO2016046156A8 (en) Substituted oxopyridine derivatives
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
PH12021550872A1 (en) Therapeutic compounds
TN2016000107A1 (en) Substituted phenylalanine derivatives
MY150931A (en) Substituted oxazolidinones and their use
JOP20170113B1 (en) Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2021004860A (en) Novel pyridazines.
WO2015165933A3 (en) Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2019012153A (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof.
TN2015000523A1 (en) Substituted benzoxazoles
DOP2024000024A (en) SUBSTITUTED S-ALANINATE DERIVATIVES
AU2016224843A8 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders